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Background. Wearable cardioverter defibrillator (WCD) therapy is feasible and safe in patients as a transient protection against
sudden cardiac death (SCD). However, the impact of WCD therapy on quality of life (QoL) has not been studied.Methods. In our
single-centre study, 109 consecutive patients with a prescription of WCD were retrospectively analysed. Quality of life has been
assessed by a standardized questionnaire (EQ-5D-3L, modified). Additionally, clinical baseline and follow-up data and recorded
arrhythmic episodes were evaluated. Results. Mean WCD therapy time was 56.2 (± 42.4) days, with a daily wear time of 19.7 (±
5) hours. A total of 3441 arrhythmia episodes were detected. Of these, 27 (1%) were adequate but did not require shock therapy.
Likewise, no inadequate shock therapy occurred. WCD therapy negatively affected quality of life: 43% of patients reported mental
health issues. 37% reported pain or discomfort. Self-care, usual activities, and mobility were restricted in 17%, 48%, and 36%,
respectively. 29% were afraid of receiving shock therapy, and 48% suffered from sleep disturbance. However, 64% indicated having
felt safe during WCD therapy. Accordingly, average quality of life was rated 70/100 points. Conclusion. In our cohort, no SCD was
prevented by WCD therapy. In contrast, in this preliminary study quality of life was reduced. Thus, careful recommendation of
WCD therapy for high risk patients should be considered.
1. Background
Sudden cardiac death (SCD) causes approximately 4.25
million deaths every year worldwide [1]. Implantable car-
dioverter defibrillator is the established therapy for prevent-
ing sudden cardiac death due to ventricular arrhythmia. In
recent years, the wearable cardioverter defibrillator therapy
(WCD, LifeVest) has been introduced as an option for a
transient time period in patients at risk for SCD while
permanent ICD therapy is not suitable, e.g., due to new onset
of cardiomyopathy or infectious issues. Technical aspects and
limitations of WCD, as well as potential areas of technical
improvement, were described by Agarwal et al. recently [2].
WCD has been shown to be feasible and safe in prevention of
SCD without relevant events of inappropriate therapy [3–7].
In the recently presented randomized VEST trial on
2302 postmyocardial infarction patients (American College
of Cardiology Annual Scientific Session/ACC 2018, Orlando,
FL, March 10, 2018), prescription of WCD was able to reduce
the second endpoint all-causemortality (reduction of relative
risk: 35.5%). However, the primary endpoint of SCD and
ventricular arrhythmia death was not significantly different
[8].
Accordingly, WCD therapy has been recommended by
the guidelines of the European Society of Cardiology in 2015
for the management of patients with ventricular arrhythmias
and the prevention of SCD in patients with severely reduced
systolic left ventricular ejection fraction who are at risk of
SCD but do not qualify for an implantable defibrillator (yet),
e.g., patients with new onset myocarditis or cardiomyopathy
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and patients with arrhythmias in the early phase postmyocar-
dial infarction or as a bridge to (a new) transvenous ICD
implantation.
For both WCD and ICD therapy, many patients have
to be treated with the WCD to prevent one SCD. WCD is
an expensive therapy and is accompanied by problems with
reimbursement, as previously reported in a European multi-
centre experience [9].
Moreover, all patients treated with the WCD have to take
upon the associated discomfort (e.g., weight of the defibril-
lator vest, sleep disturbance, and sexual intercourse), while
only very few are actually saved fromSCD.Although thismay
obviously have an impact on patients QoL, the effect ofWCD
therapy on QoL has not been studied methodically yet. Thus,
we present our preliminary experience with a cohort ofWCD
patients with a special focus on the influence on QoL.
2. Methods
We conducted a single-centre retrospective investigation
of consecutive patients who were prescribed with a WCD
(LifeVest 4000) manufactured by Zoll, PA, USA, fromMarch
2012 to February 2016.
WCD therapy was prescribed to patients with high risk
for SCD who were not eligible for ICD therapy at the time
of diagnosis, at the discretion of the treating cardiologist.
Data were collected from routine clinical management of
in-hospital patients and also in outpatient settings. Baseline
characteristics were raised at the initial presentation before
beginning of WCD therapy. Every patient presented at least
one more time, most commonly in an outpatient setting, at
the end of WCD wear time. At this time point, echocar-
diographic reevaluation of left ventricular ejection fraction
(LVEF), detailed anamnesis, and a physical examination were
performed. Conclusively, a decision on ICD implantationwas
made. Within the scope of anamnesis, QoL was assessed
with a standardized questionnaire (EQ-5D-3L, as described
elsewhere [10]). The questionnaire was extended by dichoto-
mous questions concerning fear of shock, feeling safe, sleep
disturbance, and impairment of usual activities subjectively
caused specifically by WCD therapy.
The retrospective analysis was conducted in accordance
with the declaration of Helsinki and was approved by the
ethics committee of the University of Munich (project num-
ber 17-662).
All data are presented as mean ± SD for continuous
variables. For categorical variables number of cases or per-
centage was reported. T tests were performed for comparison
of continuous variables. Categorical variables were compared
using a chi-squared test. A p value < 0.05 was considered
statistically significant. Statistical analyses were performed
with SPSS software, version 23, IBM Corp., Armonk, NY,
USA.
3. Results
A total of 109 consecutive patients were included in our
study. Baseline characteristics of our cohort are depicted in
Table 1. The predominant indication for WCD prescription
Figure 1: The five standard items of EQ-5D-3L are depicted
[percentage of patients]. Severe impairments are shown in black bars
and mild impairments in grey bars. Patients stating no impairment
are depicted in white bars.
was primary prophylactic. Patients had symptomatic systolic
heart failure with reduced LVEF. Correspondingly, current
medication consists of medical heart failure therapy. 78
patients presented with newly diagnosed nonischemic or
ischemic cardiomyopathy or were after acute myocardial
infarction. 31 patients already had an ICD implanted but
were temporarily not eligible for ICD therapy because of ICD
explantation due to device infection or complications with
ICD leads.
Mean wear time of the WCD was 56.2 ± 42.4 days, with a
daily wear time of 19.7 ± 5.0 hours per day.
In total, 3441 episodes were detected.The vast majority of
episodes were inadequate (3414, 99%), mostly due to noise
(2734, 80%), oversensing (659, 19%), and supraventricular
tachycardia (21, <1%).There were 27 (<1%) adequate episodes
due to sustained VTs in four patients (two patients after
acute myocardial infarction, one patient with ICM but
without acute myocardial infarction, and one patient with
myocarditis). No single adequate or inadequate shock therapy
occurred, either because episodes terminated spontaneously
or therapy was inhibited by the patients by pressing the
response button of the WCD.
All patients with preexisting ICD therapy received de
novo implantation of an ICD after WCD therapy.
LVEF had improved significantly at the end ofWCDwear
time (31.8 ± 13.9 versus 37.6 ± 13.1; p<0.01). Accordingly, only
35 of 78 patients without preexisting ICD therapy received de
novo ICD implantation.
Complete data on QoL (modified EQ-5D-3L question-
naire, as described above) was accessible in 87 patients (all 78
patients without prior ICD therapy and 9 patients after ICD
explantation).
The levels of impairment of the 5 different items of
EQ-5D-3L are depicted in Figure 1. Mobility was severely
reduced in 2% and mildly in 30%. The ability of self-care
(e.g., washing and dressing) was severely diminished in 1%
and mildly in 16%. 1% of patients reported having severe
problems in accomplishing their daily routine activities (e.g.,
job, housekeeping), and 24% had mild problems. Severe pain
was reported by 5% and mild pain by 31%, respectively. 43%
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Table 1: Patient’s characteristics.
All patients ICM DCM Others
n 109 46 (42%) 47 (43%) 16 (15%)
Age (years) 58 ± 16 68 ± 16 54 ± 16 44 ± 16
Male sex (%) 85 (78%) 42 (91%) 34 (72%) 9 (56%)
After acute myocardial infarction 16 (15%) 16 (35%) 0 0
LV-EF (%) 32 ± 14 36 ± 15 26 ± 9 38 ± 17
Indication
Primary prophylactic 81 (74%) 29 (63%) 42 (89%) 10 (63%)
Secondary prophylactic 38 (26%) 17 (37%) 5 (11%) 6 (37%)
Functional status
NYHA I 11 (10%) 7 (15%) 1 (2%) 3 (19%)
NYHA II 44 (40%) 23 (50%) 15 (32%) 5 (31%)
NYHA III 44 (40%) 16 (35%) 22 (47%) 6 (37%)
NYHA IV 9 (8%) 0 (0%) 8 (17%) 1 (6%)
Cardiovascular risk factors
Diabetes mellitus 30 (28%) 17 (37%) 11 (23%) 2 (13%)
Smoking 48 (44%) 24 (52%) 18 (38%) 6 (38%)
Hypercholesterolaemia 52 (48%) 32 (70%) 16 (34%) 4 (25%)
Hypertension 55 (50%) 34 (73%) 17 (36%) 4 (25%)
Creatinine (mg/dl) 1.2 ± 0.6 1.2 ± 0.6 1.3 ± 0.6 1.0 ± 0.6
Current medication
Beta blocker 103 (94%) 45 (98%) 45 (96%) 13 (81%)
Inhibitors of ACE or AR 95 (87%) 42 (91%) 42 (89%) 11 (69%)
Diuretics 86 (79%) 32 (70%) 45 (96%) 9 (57%)
Aldosterone antagonist 85 (78%) 34 (74%) 41 (87%) 10 (63%)
Amiodarone 7 (6%) 2 (4%) 5 (11%) 0 (0%)
NYHA: New York heart association, ACE: angiotensin converting enzyme, AR: angiotensin receptor.
had mild mental health (e.g,. depression and anxiety) issues,
whereas no patient reported severe mental health issues.
The overall subjective state of health, on a visual analogue
scale from 0 to 100 points, was averagely 70 points.
The dichotomous questions specifically addressing the
subjective perception during WCD therapy revealed that
29% were afraid of receiving shock therapy. WCD related
sleep disturbance or impairment of daily routine activities
was reported by 48%. Only 64% reported feeling adequately
protected by the WCD (Figure 2(a)).
Additionally, the influence of the number of warning
signals that occurred during WCD therapy on the dichoto-
mous items was analysed. 44 patients experienced 3 (mean
0.7±1) or less warning signals, and 43 experienced more
than 3 (mean 72±147), respectively. More warning signals
significantly increased fear of shock therapy (18 versus 40%;
p=0.03), and there was a trend towards increased sleep
disturbance (41 versus 56%; p=0.16). Subjective impairment
of daily routine activities (50 versus 47%; p=0.75) and the
feeling of being protected (66 versus 63%; p=0.76) were not
affected by the number of warning signals, at all (Figure 2(b)).
35 of 78 patients without prior ICD therapy received an
ICD after the WCD therapy. Compared to patients with ICD
implantation, patients without ICD implantation at the end of
WCD therapy reported having felt more safe (77 versus 51%;
p<0.01) without significant differences of the fear of shock
(35 versus 26%; p=0.39), WCD related sleep disturbance (51
versus 49%; p=0.8), and restriction of daily activities (58
versus 40%; p=0.11; Figure 2(c)).
4. Discussion
To the best of our knowledge, this is the first study to
examine the impact of WCD therapy on QoL. As Sears et al.
stated, although no universal definition of QoL exists, QoL
is a generic term for a multidimensional health outcome, in
which biological, psychological, and social functioning are
interdependent [11]. In summary, our major findings are that
in a standardized QoL questionnaire every 3rd to 6th patient
reported mild issues and 1 to 2 percent complained about
severe issues. Of note, in dichotomous questions specifically
addressing the subjective situation during WCD use, one-
third of patients reported fear of shock treatment and half
of patients felt disturbed during their sleep and restricted in
daily routine activities. Furthermore, there was a correlation
between number of alarms given by the WCD for pending
shock therapy and patients who reported QoL issues. This
stands in contrast to a short report by the manufacturer of
theWCD LifeVest (Zoll) [12]. In the survey, patients reported
by telephone interview to predominantly feel well protected
(88%), 82% felt more confident in daily routine activities, and
72% reported an improvement in sleep, whereas our study
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Figure 2:The additional items referring toWCD relatedQoL are depicted [percentage of patients]. (a)Without subgroups. (b)With subgroup
differentiation comparing patients with 3 or lessWCDwarning signals (grey bar; n=44) to patients with at least 3WCDwarning signals (white
bars; n=43). (c)With subgroup differentiation comparing patients with (striped bars; n=35) and without (white bars: n=43) ICD implantation
after WCD therapy.
shows a substantial impairment of QoL associated with all
these features. As the most alarms were given for inadequate
episodes, it is obvious that development is needed to decrease
the number of inadequate episodes and inadequate therapy
warning signals to decrease the patients fear during WCD
therapy.
Interestingly, we observed a discrepancy in the perception
of QoL when patients were asked about their general condi-
tion and their condition with specific view on the situation
under WCD therapy. For example, when patients were asked
to rate their restrictions in daily routine, the same patients at
the same time considered their restrictionsmore severe when
specifically asked about WCD therapy (Figures 1 and 2(a)).
In our cohort, 78 patients received a WCD without
existing prior ICD therapy. Taken into consideration that
only 35 patients required ICD implantation at the end of
WCD therapy (meaning that the remaining 43 patients who
did not receive an ICD presumably suffered from less severe
heart failure at the end ofWCD therapy), impairment of QoL
might have been predominantly caused by WCD therapy.
Interestingly, patients without ICD implantation more often
reported having felt safe during WCD therapy. This might
be confounded by the patient’s relief after an improvement
of systolic function. Nevertheless, impairment of the other
items (sleep disturbance, restriction of daily activity, and fear
of shock) was even more pronounced in these patients.
Comparing our findings with data on QoL in patients
with ICD therapy, we found that the results of randomized
trials are sparse and difficult to compare as no standard tool
for measurement of QoL exists [11, 13–16]. To sum up, QoL
in ICD patients who do not receive shock therapy resem-
bles that in non-ICD patients, while QoL in ICD patients
who experience shock therapy is diminished [16]. Again,
impairment of QoL may be driven by shock therapy and
not the presence of heart failure itself. Comparing patients
with ICD to patients without ICD but with antiarrhythmic
drug therapy, it has been shown that QoL is maintained
in ICD treated patients but diminished in patients with
antiarrhythmic therapy. This states the impression that ICD
therapy (without shock therapy) is beneficial for QoL.
In contrast our findings are suggestive of the idea that
WCD therapy without shock therapy falls short of these
beneficial effects on QoL resulting in poor compliance with
an average daily wear time of only 82%. Our findings are
in accordance with the latest presented results from the
VEST trial. In this trial 2302 patients after acute myocardial
infarction and an impairment of left ventricular ejection
fraction <35% were randomized to standard care plus WCD
or standard care (in a 2:1 ratio). Mean wear time of all
for WCD therapy randomized patients was only 59%. The
authors hypothesized that this could be due to side effects like
rash (12.9 of WCD patients versus 3.8% of control patients;
p<0.001) or itching on torso (14.5 of WCD patients versus
3.1% of control patients; p<0.001) [8].
As we know from other studies on WCD therapy [3–
5, 17, 18], the overall incidence rate of shock therapy is low;
therefore the number needed to treat to save one patient
from SCD by WCD therapy will be quite high and it is an
expensive therapy (in Germany the monthly cost amounts to
roughly 2650 euros). In addition, WCD therapy remarkably
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diminishes QoL in our collective. Therefore proper patient
selection is crucial. A WCD should not be administered to
every patient with severely reduced LVEF. Instead, which
patients are most suitable for and profit most from WCD
therapy has to be determined having regard to current
trials like, for example, the Danish trial [19], and results
of upcoming prospective trials in patients with de novo
diagnosis of severe cardiomyopathy who are at high risk for
arrhythmic SCD.
4.1. Limitations. Our study has several important limitations.
First the study designwas retrospective and our cohort is very
heterogeneous. That means not all patients were prescribed
with aWCD for new onset of severe systolic heart failure for a
certain time period, but there were also subjects in our cohort
who already had permanent ICD therapy and were equipped
with the WCD for a short time to bridge to surgery, e.g.,
for ICD lead complications. Second, QoL data could not be
acquired from every subject.Therefore, it cannot be excluded
that there is a certain reporting bias. In addition, complete
QoL questionnaire was only available in nine patients with
explanted ICD.
Third, our analysis is lacking in a control group of patients
with ICD or a control group with heart failure but without
ICD or WCD.Therefor we cannot rule out an impairment of
QoL due to the heart failure itself.
5. Conclusion
In our cohort, no SCD was prevented by WCD therapy.
In contrast, in this preliminary study quality of life was
reduced. Thus, careful recommendation of WCD therapy for
high risk patients should be considered and strategies should
be developed to decrease patients' discomfort and increase
patients compliance by optimising the WCD fit, specific
patient information, and therapy of anxiety in patients at
high risk for SCD. Besides, technical development of WCD
is needed to decrease the number of inadequate episodes.
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